---
title: "monumental-1"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> 🌱 created from: [[bite_rrmm]]

# monumental-1

- Design: Phase 1 study
- Number of patients: 232
- Patients characteristics: Heavily pretreated relapsed or refractory multiple myeloma patients
- Agent: Talquetamab, administered intravenously or subcutaneously in doses ranging from 0.5 to 180 μg per kilogram of body weight
- Treatment line: Patients who had received a median of six previous lines of therapy
- Trial Acronym: MonumenTAL-1, ClinicalTrials.gov number NCT03399799

| Parameter                   | Result                                                |
| --------------------------- | ----------------------------------------------------- |
| Response rate               | 70% at 405 μg dose, 64% at 800 μg dose                |
| Median duration of response | 10.2 months at 405 μg dose, 7.8 months at 800 μg dose |

- Highlight of toxicity: Common adverse events included cytokine release syndrome, skin-related events, and dysgeusia, primarily low-grade.
  - skin, nail, tounge
  - 味覺障礙（英語：Dysgeusia）指的是味覺的扭曲或失真。味覺障礙通常與喪失味覺、味覺遲鈍有關。味覺障礙可能是某個疾病的主要症狀或次要症狀。
- One line summary: Talquetamab showed significant response in heavily pretreated relapsed or refractory multiple myeloma patients with manageable toxicity.
